The shares of Change Healthcare Inc. (NASDAQ:CHNG) has been pegged with a rating of Outperform by Raymond James in its latest research note that was published on December 20, 2019. Raymond James wasn’t the only research firm that published a report of Change Healthcare Inc., with other equities research analysts also giving their opinion on the stock. The stock had earned Buy rating from Deutsche Bank Markets when it published its report on September 26, 2019. That day the Deutsche Bank set price target on the stock to $15. Wells Fargo was of a view that CHNG is Market Perform in its latest report on July 22, 2019. SVB Leerink thinks that CHNG is worth Outperform rating. This was contained in the firm’s report on July 22, 2019 in which the stock’s price target was also moved to 20.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 1 believe it has the potential for further growth, thus rating it as Hold while 15 advised investors to purchase the stock. The consensus currently stands at a Buy while its average price target is $18.53. The price of the stock the last time has raised by 41.10% from its 52-Week high price while it is -9.73% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 51.30.
The shares of the company added by 1.47% during the trading session on Wednesday, reaching a low of $15.485 while ending the day at $15.86. During the trading session, a total of 9.62 million shares were traded which represents a -479.73% decline from the average session volume which is 1.66 million shares. CHNG had ended its last session trading at $15.63. Change Healthcare Inc. debt-to-equity ratio currently stands at 31.91, while its quick ratio hovers at 1.40 CHNG 52-week low price stands at $11.24 while its 52-week high price is $17.57.
The company in its last quarterly report recorded $0.27 earnings per share which is above the predicted by most analysts. The Change Healthcare Inc. generated 3.41 million in revenue during the last quarter. Change Healthcare Inc. has the potential to record 1.42 EPS for the current fiscal year, according to equities analysts.
Investment analysts at DA Davidson published a research note on February 28, 2019 where it informed investors and clients that Fitbit Inc. (NYSE:FIT) is now rated as Buy. Their price target on the stock stands at $7. Wedbush also rated FIT as Downgrade on February 22, 2019, with its price target of $6.50 suggesting that FIT could surge by 11.56% from its current share price. Even though the stock has been trading at $6.56/share, analysts expect it to down by -0.91% to reach $7.35/share. It started the day trading at $6.62 and traded between $6.46 and $6.50 throughout the trading session.
A look at its technical shows that FIT’s 50-day SMA is 6.61 while its 200-day SMA stands at 5.04. The stock has a high of $7.26 for the year while the low is $2.81. The stock, however, witnessed a rise in its short on 01/31/20. Compared to previous close which recorded 76.28 M shorted shares, the short percentage went higher by 4.42%, as 79.65M CHNG shares were shorted. At the moment, only 33.70% of Fitbit Inc. shares were sold short. The company’s average trading volume currently stands at 7.51M shares, which means that the short-interest ratio is just 10.16 days. Over the past seven days, the company moved, with its shift of -1.52%. Looking further, the stock has dropped -7.14% over the past 90 days while it gained 97.57% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The The Vanguard Group, Inc. sold more FIT shares, decreasing its portfolio by -0.18% during the last quarter. This move now sees The The Vanguard Group, Inc. selling -46,806 shares in the last quarter, thus it now holds 26,138,034 shares of FIT, with a total valuation of $170,419,982. Goldman Sachs & Co. LLC (Private . meanwhile bought more FIT shares in the recently filed quarter, changing its stake to $131,239,183 worth of shares.
Similarly, BlackRock Fund Advisors decreased its Fitbit Inc. shares by 1.54% during the recently filed quarter. After selling 16,269,675 shares in the last quarter, the firm now controls -253,902 shares of Fitbit Inc. which are valued at $106,078,281. In the same vein, Magnetar Financial LLC decreased its Fitbit Inc. shares by during the most recent reported quarter. The firm bought 12,773,265 shares during the quarter which decreased its stakes to 12,773,265 shares and is now valued at $83,281,688. Following these latest developments, around 0.30% of Fitbit Inc. stocks are owned by institutional investors and hedge funds.